Under this new arrangement, the companies will work together to further develop Indomo’s DT-001 candidate, which will be combined with the ClearPen device to allow self-treatment of inflammatory acne lesions.

In efforts to streamline its portfolio and prioritize core capabilities, the company has agreed two separate transactions to divest its CDMO and Cell Solutions as well as select European Discovery Services sites.

The companies will integrate their strengths from early-stage development and commercial-scale GMP API manufacturing to offer clients an end-to-end API solution.

Kidswell Bio and Treehill Partners have joined forces to create a new company aimed at accelerating the clinical development of a novel SHED stem cell therapy showing early efficacy signals for pediatric cerebral palsy (CP).

With a looming patent cliff, continuing geopolitical pressures, and regionalized supply chains, there is a need for new creative deal structures and alternative financing to ensure successful M&A momentum.

A manufacturing collaboration between ten23 health and BD will support the commercialization of a wearable injector platform that offers a ready-to-use option for subcutaneous administration of high-dose biologics.

The agreement will allow AbbVie to develop, manufacture, and commercialize RemeGen’s novel PD-1/VEGF bispecific antibody in combination with its ADCs across multiple solid tumors.

Insilico Medicine has entered a multi‑year R&D collaboration with Servier to discover and develop novel AI‑designed oncology therapies. The deal will combine Insilico’s Pharma.AI platform with Servier’s global oncology development and commercialization capabilities.

Sweden’s Nanexa has entered a licensing and option deal with Moderna, granting access to its PharmaShell drug delivery platform to develop long-acting versions of Moderna’s mRNA-based therapies.

To strengthen its European presence and enhance high-impact event experiences for life science clients worldwide, ITA Group has acquired C2events, a UK-based event management agency specializing in healthcare and pharmaceutical conferences.

A collaboration between Rentschler Biopharma and Coriolis Pharma has been formed that will draw upon complementary scientific and technical expertise to provide end-to-end solutions for the biopharmaceutical value chain.

A strategic research collaboration has been announced by Biogen and Dayra Therapeutics aimed at the discovery and development of oral macrocyclic peptides that could disrupt traditional antibody-based treatments.

In collaboration with A.forall and IMGA, Nanoform has formed a new subsidiary aimed at outlicensing Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or value-added generic medicine opportunity.

The companies have entered into a definitive agreement for the acquisition, which includes an investigational immunotherapy preclinical candidate and a proprietary RNA modular platform.

Through the purchase the contract packaging organization will add 160,000 sq. ft. of manufacturing and warehouse facilities in Florida and will expand its capabilities and market segments.

A deal worth up to USD 5.7 billion has been unveiled that is aimed at the development of molecular glue degraders for immune-mediated diseases utilizing Monte Rosa’s AI-driven QuEEN platform.

The companies have joined forces to launch an advanced lipid nanoparticle platform for RNA medicine delivery to advance the next generation of gene and vaccine therapies.

The latest multi-asset licensing and option agreement between Argos and Novartis, will grant the Swiss pharma giant rights to key siRNA molecules, building on the companies’ partnership.

This partnership will leverage BioDuro’s expertise and Atombeat’s in silico modeling know-how to launch an AI-powered platform that allows for accelerated development of next-generation peptides.

The companies will work together, leveraging Syntekabio’s AI prediction platform for virtual screening to uncover new, high-potential indications for MetaVia’s DA-1241 oral therapy.